Together with previous preclinical evidence, our data provide an additional rationale to implement novel clinical trials testing COX-2 inhibitors’ potential to prevent NSCLC immune evasion, as well as to enhance the anti-tumor activity of PD-1/PD-L1 based immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.